Clinical Trial: A Study to Evaluate the Safety, PK, and Immunogenicity of Recombinant Human Hyaluronidase in Healthy Subjects

U.S., March 21 -- ClinicalTrials.gov registry received information related to the study (NCT07484893) titled 'A Study to Evaluate the Safety, PK, and Immunogenicity of Recombinant Human Hyaluronidase in Healthy Subjects' on Feb. 24.

Brief Summary: The study is being conducted to evaluate the safety, pharmacokinetics, and immunogenicity of recombinant human hyaluronidase in healthy Chinese adult male subjects.

Study Start Date: May 14

Study Type: INTERVENTIONAL

Condition: Healthy Adult Male

Intervention: DRUG: recombinant human hyaluronidase

HLXTE-HAase02 is a proprietary recombinant human hyaluronidase, with a molecular weight of approximately 49 kDa, is expressed in Chinese Hamster Ovary (CHO) cells and is intended for formulation ...